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Abstract
Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are types of major TDP-43
(43-kDa TAR DNA-binding protein) proteinopathy. Cortical TDP-43 pathology has been analyzed in detail in cases of
FTLD-TDP, but is still unclear in cases of ALS. We attempted to clarify the cortical and subcortical TDP-43 pathology
in Japanese cases of sporadic ALS (n = 96) using an antibody specific to phosphorylated TDP-43 (pTDP-43). The
cases were divided into two groups: those without pTDP-43-positive neuronal cytoplasmic inclusions in the
hippocampal dentate granule cells (Type 1, n = 63), and those with such inclusions (Type 2, n = 33). Furthermore,
the Type 2 cases were divided into two subgroups based on semi-quantitative estimation of pTDP-43-positive
dystrophic neurites (DNs) in the temporal neocortex: Type 2a (accompanied by no or few DNs, n = 22) and Type 2b
(accompanied by abundant DNs, n = 11). Clinico-pathologic analysis revealed that cognitive impairment was a
feature in patients with Type 2a and Type 2b, but not in those with Type 1, and that importantly, Type 2b is a
distinct subtype characterized by a poor prognosis despite the less severe loss of lower motor neurons, the unusual
subcortical dendrospinal pTDP-43 pathology, and more prominent glial involvement in cortical pTDP-43 pathology
than other two groups. Considering the patient survival time and severity of motor neuron loss in each group,
transition from Type 1 to Type 2, or from Type 2a to Type 2b during the disease course appeared unlikely.
Therefore, each of these three groups was regarded as an independent subtype.
Keywords: Amyotrophic lateral sclerosis, Frontotemporal lobar degeneration, TDP-43, Cerebral cortex, Putamen,
Globus pallidus, Dystrophic neurite, Dendrites
Introduction
Amyotrophic lateral sclerosis (ALS), an adult-onset, fatal
neurodegenerative disorder, is the most common type of
motor neuron disease (MND). Most cases (90-95 %)
appear to occur randomly without a family history
(sporadic ALS) [1, 2]. The principal feature is
progressive muscular weakness due to degeneration of
both the upper and lower motor neuron systems, and
characteristic ubiquitin-positive neuronal cytoplasmic
inclusions (NCIs) are present in the lower motor neurons
[3–5]. It has also been well recognized that there are
sporadic ALS cases accompanied by cognitive impairment
(ALS or MND with dementia: ALS-D or MND-D), in
which the presence of ubiquitin-positive NCIs and dys-
trophic neurites (DNs) in the extra-motor cortices, includ-
ing the hippocampal dentate gyrus, is a significant feature
[5–9]. Similar ubiquitin pathology has also been demon-
strated in a subset of patients with frontotemporal demen-
tia (FTD) with or without MND [10]. Accordingly, it has
been suggested that ALS, ALS-D (MND-D) and FTD
without MND represent a clinico-pathologic spectrum [6].
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Since the identification of a nuclear protein, 43-kDa TAR
DNA-binding protein (TDP-43, also known as TARDBP), as
the major component of the ubiquitinated inclusions in
frontotemporal lobar degeneration with ubiquitin-positive,
tau-and α-synuclein-negative inclusions (FTLD-U) and ALS
[11, 12], many studies of such cases employing TDP-43 im-
munohistochemistry have been performed [13–18]. This has
led to the recognition that the clinico-pathologic spectrum
encompassing ALS at one end and FTD at the other repre-
sents a new concept of TDP-43 proteinopathy [19, 20].
Cases of FTLD-U were originally divided into three types
by two independent groups using their own classification
systems based on the morphology and anatomical distribu-
tion of cortical ubiquitin neuronal lesions, including NCIs
and DNs [21, 22]. After confirmation that the majority of
FTLD-U cases in fact represent FTLD-TDP, these two
classification systems were integrated into a ‘harmonized
classification system’ that included four types (Types A, B,
C and D) of FTLD-TDP pathology [23], the new Type D be-
ing associated with mutations of the VCP (valosin-contain-
ing protein) gene [24, 25]. In this new classification system,
MND with FTD (so-called ALS-D) was regarded as a com-
mon phenotype of Type B, being characterized by moderate
numbers of NCIs and very few DNs throughout all cortical
layers. However, one of the above studies demonstrated that
7 of 10 cases that were sporadic and exhibited MND in
addition to dementia had cortical ubiquitin pathology
characterized by a mixture of numerous NCIs and frequent
small DNs [22], corresponding to Type A of the new
classification system mentioned above [23]; this finding
suggested that the cortical ubiquitin pathology in ALS-D
and/or FTLD-MND could be heterogeneous.
Using a phosphorylation-independent anti-TDP-43 anti-
body, we have previously demonstrated that immunoposi-
tive NCIs and glial cytoplasmic inclusions (GCIs) can
occur in many brain regions in ALS, and that cases can be
classified into two types – type 1 and type 2–based on the
distribution pattern of NCIs in the CNS and hierarchical
cluster analysis of the pattern [17]. Type 2 can be distin-
guished from type 1 by the presence of TDP-43-positive
NCIs in the extra-motor neuron system, including the
frontotemporal cortex, hippocampal formation, neostria-
tum and substantia nigra, and is significantly associated
with dementia [17]. Since a monoclonal antibody specific-
ally recognizing abnormally phosphorylated TDP-43 has
become available, we have often noticed the presence of
abundant threads, or dot-like or granular DNs in the
temporal neocortex in cases of ALS, more strictly those
with NCIs in the hippocampal dentate granule cells.
In the present study, we attempted to reevaluate the
cortical and subcortical TDP-43 pathology in cases of spor-
adic ALS using the above monoclonal antibody, which
never recognizes endogenous non-phosphorylated TDP-43
in nuclei, thus allowing unambiguous identification of
pathologic structures. The results obtained eventually
allowed us to classify the examined cases into three patho-
logic groups, whose clinical, pathologic and biochemical
features were then analyzed.
Materials and methods
The present study was conducted within the framework of
a project, “Neuropathologic and Molecular-Genetic Inves-
tigation of CNS Degenerative Diseases”, approved by the
Institutional Review Board of Niigata University. Informed
consent was obtained from the patients’ families prior to
genetic analyses.
Subjects
We retrieved all cases of pathologically confirmed ALS
from our institutional autopsy files covering the period
between 1975 and 2013, reviewed the medical records and
identified 128 cases of clinically sporadic ALS without any
family histories of similar neurological disorders. All of
the patients were of Japanese ancestry, and their clinical
information was obtained retrospectively by reviewing
their medical records.
Among these 128 cases, the tissue samples were of poor
quality due to complications of infarction, etc. and/or
sampling in 26 cases, pathologic features indicative of
complications arising from other major neurodegenerative
diseases affecting the cerebral cortex and basal ganglia
were evident in 4 cases (Alzheimer’s disease = 2; progres-
sive supranuclear palsy = 1; multiple system atrophy = 1),
and no TDP-43-positive inclusions were detected in the
CNS, including the lower motor neurons, in 2 cases.
Accordingly, a total of 32 cases were excluded, leaving 96
cases (58 male, 38 female; mean age 67.4 years, standard
deviation 9.8 years, range 36–87 years) for analysis. Seven
cases were found to have only a few Lewy bodies, with α-
synuclein-positive NCIs and DNs confined to the brain-
stem. These cases were considered to be incidental
Parkinson’s disease and were included in the present
study. All of the studied cases showed loss of upper and
lower motor neurons as well as ubiquitin-positive skein-
like inclusions in the remaining lower motor neurons, and
Bunina bodies were evident in the remaining lower motor
neurons in 91 of the 96 cases.
Histology and immunohistochemistry
Multiple formalin-fixed, paraffin-embedded CNS tissue
blocks for all cases were available for the present study.
For the motor cortex, frontal cortex (including the pre-
frontal area), temporal cortex (including the hippocam-
pus), basal ganglia, hypoglossal nucleus, and cervical and
lumbar anterior horns, 4-μm-thick sections stained with
hematoxylin-eosin (H-E) were used for semi-quantitative
analysis employing a 4-point scale (0, absent; 1, mild; 2,
moderate; 3, severe) of neuronal cell loss (Additional file
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1: Figure S1). FTLD was diagnosed by the presence of at-
rophy and neuronal loss with gliosis in the frontotemporal
cortices, regardless of severity. The study was carried out
by two of the authors (R.T. and M.T.), and reviewed by
two other investigators (Y.T. and H.T.) to ensure evalu-
ation consistency.
Newly prepared 4-μm-thick sections were cut from the
temporal cortex (including the hippocampus), frontal and
motor cortices and basal ganglia for immunohistochemi-
cal studies. The sections were autoclaved at 120 °C in
10 mM citrate buffer, pH 6.0, for 10 min, and then immu-
nostained with a mouse monoclonal antibody against
phosphorylated TDP-43 (pTDP-43; phospho Ser409/410)
(clone 11–9; Cosmo Bio Co., Ltd., Tokyo, Japan; 1:5000).
Selected sections were also immunostained with a rabbit
polyclonal phosphorylation-independent anti-TDP-43
antibody (10782-2-AP; Protein Tech Group Inc., Chicago,
IL; 1:4000). Immunolabeling was detected using the
peroxidase-polymer-based method using a Histofine Sim-
ple Stain MAX-PO kit (Nichirei Biosciences Inc, Tokyo,
Japan) with diaminobenzidine (DAB) as the chromogen.
To estimate the neuropathological staging of changes
associated with Alzheimer’s disease, we performed
Gallyas-Braak silver impregnation, and immunohisto-
chemistry using mouse monoclonal antibodies against
hyperphosphorylated tau protein (AT8; Innogenetics,
Ghent, Belgium; 1:200) and β-amyloid (Dako, Glostrup,
Denmark; 1:100). Then, we evaluated the Braak stages of
neurofibrillary tangles and amyloid deposits [26, 27], and
also estimated the level of Alzheimer’s disease-related
neuropathologic change based on ‘ABC’ score [26–30].
Classification procedure based on cortical pTDP-43
pathology
In our previous study of a series of 35 cases of sporadic
ALS using a phosphorylation-independent antibody
against TDP-43, we found that two pathologic phenotypes
– type 1 and type 2 – were distinguishable as mentioned
above, and that all cases showing TDP-43-positive NCIs
in the hippocampal dentate granule cells were classifiable
into type 2, whereas all cases except one showing no such
NCIs were classifiable into type 1 [17]. Therefore, we first
divided the 96 cases investigated in the present study into
two groups: one without pTDP-43-positive NCIs in the
dentate granule cells (Type 1, n = 63) and the other with
such inclusions (Type 2, n = 33) (Fig. 1a, b). We then
performed a semi-quantitative estimation of pTDP-43-
positive DNs in the temporal neocortex of individual cases
in each group. The DNs appeared almost exclusively as
threads, and granular and dot-like structures. Cases in
which many such pTDP-43-positive DNs were evident
were classed as having abundant DNs, whereas cases in
which such DNs were a much less prominent feature were
classed as having no DNs, or few DNs, if any. Cases of
Type 2 were divided into two subgroups: Type 2 accom-
panied by no or few DNs (Type 2a, n = 22) and Type 2
accompanied by abundant DNs (Type 2b, n = 11) (Fig. 1 a,
c). No cases showed an “intermediate” density of DNs, or
were unclassifiable to either subgroup. An important
observation was that the density of pTDP-43-positive
NCIs in the temporal cortex appeared to vary randomly,
which meant that classification into specific groups on the
basis of NCI density was not possible. In cases belonging
to the other group, Type 1, no pTDP-43-positive DNs
were evident in the temporal neocortex, and therefore
further subdivision of this group was not possible at this
stage. NCIs and DNs visualized using anti-pTDP-43 were
also recognizable with phosphorylation-independent anti-
TDP-43 (Fig. 1d).
Double-labeling immunofluorescence
A double-labeling immunofluorescence study was per-
formed to assess the anatomical localization of pTDP-43
deposits forming granular and dot-like DNs. Sections of
the temporal lobe and basal ganglia, including the neos-
triatum and globus pallidus from three representative
cases of Type 2b were examined using rabbit polyclonal
anti-pTDP-43 (phospho Ser409/410) (Cosmo Bio Co.,
Ltd.; 1:2000) and mouse monoclonal anti-neurofilament
H (non-phosphorylated) (SMI-32; Calbiochem, San
Diego, CA; 1:500), as well as rabbit polyclonal anti-
pTDP-43 (phospho Ser409/410) and mouse monoclonal
anti-synaptophysin (Leica Biosystems; Newcastle-upon-
Tyne, UK; 1:50). The second antibodies used were Alexa
Fluor 488 goat anti-rabbit IgG and Alexa Fluor 555 goat
anti-mouse IgG (Molecular Probes, Eugene, OR; 1:1000).
The sections were treated with an Autofluorescence
Eliminator Reagent (Millipore, Billerica, MA), mounted
under glass coverslips using VectaShield mounting
medium with 4,6-diamidino-2-phenylindole (DAPI)
nuclear stain (Vector Laboratories, Burlingame, CA),
and analyzed using a Carl Zeiss confocal laser scanning
microscope (LSM700).
Double labeling with in situ hybridization and
immunohistochemistry
The numbers of neurons and glial cells possessing cyto-
plasmic pTDP-43-positive inclusions (NCIs and GCIs)
were assessed in the motor cortex using a double-
labeling method with in situ hybridization (ISH) and
immunohistochemistry, and compared between the
three groups. For this study, we selected representative
cases of Type 1 (n = 22), Type 2a (n = 12) and Type 2b
(n = 7) among cases logged after 1990. In the Type 1
cases, a significant number of pTDP-43-positive NCIs
and GCIs were seen in the motor cortex. Therefore,
from the Type 2a and Type 2b cases, we selected cases
in which a larger number of pTDP-43-positive NCIs and
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Fig. 1 Procedure for classification of ALS-TDP pathology. (a) The procedure used for classification of the 96 cases of sporadic ALS and the results obtained.
(b) Type 1 and Type 2 are defined by absence (upper) and presence (lower) of phosphorylated TDP-43 (pTDP-43) -positive NCIs in the hippocampal
dentate granule cells, respectively. (c) Type 2a and Type 2b are defined by the presence of no or few, and abundant pTDP-43-positive DNs in the temporal
neocortex, respectively. Representative TDP-43 pathology of Type 2a and Type 2b is shown. (d) NCIs and DNs demonstrated using anti-pTDP-43 antibody
(upper) are also recognizable using phosphorylation-independent anti-TDP-43 antibody (lower). Scale bars: b= 40 μm; c= 25 μm; d= 10 μm
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GCIs were evident in the motor cortex than in the tem-
poral or frontal cortex.
ISH was performed in these three groups using newly
prepared paraffin-embedded 10-μm-thick sections from the
motor cortex, as described previously [31], with minor
modifications (Supplementary Methods). A probe for
human neurofilament 3 (hNF: 150-kDa medium) (GenBank
accession number: BC002421) was used. As a result, the
sections from 11 cases were found to be inadequate for
ISH, leaving 30 cases (Type 1, n = 16; Type 2a, n = 8; Type
2b, n = 6) logged between 1990 and 2012 for the subse-
quent immunohistochemical study.
The hybridized sections were immunostained using
mouse monoclonal anti-pTDP-43 (clone 11–9; 1:5000), and
then counterstained with Nuclear Fast Red solution (Sigma
Aldrich, St. Louis, MO). In each case, 10 sequential images
of the motor cortex were taken through a × 20 objective
lens using a single ISH-labeled and immunostained section.
The total area taken from a section from each case was
1.5 mm2, covering the cortical layers II-VI. The numbers of
hNF-positive cells with nuclei, hNF- and pTDP-43-positive
cells with nuclei, and hNF-negative and pTDP-43-positive
cells with nuclei were counted manually.
Statistical analysis
To compare clinical and pathologic features between the
three groups, we used Kruskal-Wallis test with post-hoc
Steel-Dwass test for non-parametric analysis of inde-
pendent samples, multiple regression analysis to deter-
mine whether independent variables can predict the
value of the dependent variable, Kaplan-Meier plots and
a log-rank test to compare survival distributions, and
Fisher’s exact test with Bonferroni-corrected multiple
comparisons or Ryan’s multiple comparison test for
comparison of categorical data. These statistical analyses
were performed using GraphPad Prism version 5.0
(GraphPad Software, San Diego, CA), SPSS Statistics
version 12.0 (IBM, Armonk, NY) and R version 3.1.2
(http://www.r-project.org/). Differences were considered
statistically significant at P <0.05.
Biochemical analysis of pTDP-43
Fractionation of frozen brain tissues and TDP-43 im-
munoblotting were performed on selected cases. Protein
lysates were generated from the motor cortex of Type 1
(n = 4) cases and from the temporal cortex of Type 2a
(n = 4) and Type 2b (n = 4) cases, as well as from the
frontal cortex of FTLD-TDP Type A, B and C (two
each), as described previously [32–34], with minor
modifications (Additional file 2). In order to distinguish
the 20-25-kDa band pattern clearly, we used a large
polyacrylamide gel (184 × 185 mm) and electrophoresed
the samples at 200 V for 16 h at 4 °C. The separated
samples were analyzed by immunoblotting with a mouse
monoclonal antibody against pTDP-43 (clone 11–9;
1:2000) [35].
Analysis of the TARDBP and C9ORF72 genes
The presence or absence of TARDBP and C9ORF72 gene
mutations was analyzed in cases for which frozen tissue
samples were available. High-molecular-weight genomic
DNA was extracted from 83 cases (Type 1, n = 54; Type 2a,
n = 19; Type 2b, n = 10). We amplified all the exons of the
TARDBP (NM_007375.3) gene using a series of primers,
followed by sequence reaction [36]. For screening of
GGGGCC repeat expansion in C9ORF72 (NM_018325.2),
repeat-primed PCR was performed on an ABI 3130xl
genetic analyzer (Applied Biosystems, Foster City, CA)
using Peak Scanner software v1.0 (Applied Biosystems), as
described previously [37, 38].
Results
Clinical features
The demographics and clinical features of the studied
patients are summarized in Table 1. There was no evident
difference in gender or cause of death between patients
with Type 1, and those with Type 2a and Type 2b.
However, statistical comparison among the three groups
revealed that the age at onset was higher for Type 2b than
for Type 1 (P = 0.024), and that the survival time from
disease onset was shorter for Type 2b than for Type 1 (P
<0.0001) and Type 2a (P = 0.003). Multiple regression
analysis using age at onset and ALS subtype as independ-
ent covariates and the survival time from disease onset as
a dependent variable, a significant correlation was found
between ALS subtype and the survival time from disease
onset (P = 0.039), whereas the correlation for age at onset
was not statistically significant (P = 0.106). Comparison of
initial symptoms between the three groups showed that
limb weakness was more frequent whereas bulbar and
other symptoms were significantly less frequent in Type 1
than that in Type 2a (P <0.0001) and Type 2b (P <0.01).
Cognitive impairment was present in 15 (16 %) of the 96
patients, the incidence being similar to that (10-15 %) of
overt cognitive impairment meeting the criteria for fronto-
temporal dementia reported previously in patients with
ALS [39]. The rate of occurrence of cognitive impairment
was lower in Type 1 than in Type 2a (P <0.001) and Type
2b (P <0.00001). There were no evident differences in the
age at death between cases with (n = 15) and those
without (n = 81) cognitive impairment (Mean ± SD: 67.6 ±
7.5 vs 67.4 ± 10.2 years, P = 0.959).
Pathologic features
The pathologic features of the studied cases are summa-
rized in Table 2. In the motor cortex, there were no evi-
dent differences in the severity of neuronal loss among
the three groups: Type 1, and Type 2a and Type 2b.
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However, in the spinal anterior horns (cervical and lum-
bar) and hypoglossal nucleus, loss of motor neurons was
less severe in Type 2b than in Type 1 (P <0.001 and P =
0.001, respectively) or in Type 2a (P = 0.018 and P =
0.022, respectively). No neuronal loss in the basal ganglia
was evident in any of the cases. None of the present
cases showed hippocampal sclerosis characterized by
neuronal loss and gliosis in the hippocampal formation,
which is found often in FTLD-TDP but rarely in ALS [40,
41]. The Additional file 3: Table S1 shows the neuropatho-
logical stages of Alzheimer’s disease-associated changes in
all of the 96 cases. Eighty-six, 10, and 0 cases corre-
sponded to Braak neurofibrillary stage 0-II, stage III, and
stage IV-VI, respectively. In accordance with the ‘ABC’
score [29], 93 and 3 cases corresponded to ‘low’ and ‘inter-
mediate’ levels of Alzheimer’s disease neuropathologic
change, respectively. The three patients exhibiting ‘inter-
mediate’ change showed no cognitive impairment.
In each group, a proportion of cases showed FTLD
manifested by frontotemporal atrophy and frontotemporal
cortical neuronal loss with gliosis; the rate of occurrence of
FTLD was only 6 % in Type 1, being much lower than in
Type 2a (36 %, P <0.001) or in Type 2b (64 %, P =
0.00001). In around half of the cases in both the Type 2a
and Type 2b groups, pTDP-43-positive NCIs showed a
temporal cortex-predominant distribution pattern, in
Table 1 Demographics and clinical features in three types of sporadic ALS
All Type 1 Type 2a Type 2b P-value
(n = 96) (n = 63) (n = 22) (n = 11)
Sex (male: female) 58:38 38:25 13:9 7:4 0.968
Age at onseta (years) 64.5 (32–86) 62.0 (32–86) 65.5 (50–79) 72.0* (59–82) 0.023
Survival timea (months) 22 (6–204) 33 (7–204) 20 (6–64) 12** (9–24) <0.0001
Initial symptoms <0.0001
limb 61 (64 %) 50 (79 %)*** 7 (32 %) 4 (36 %)
bulbar 32 (33 %) 13 (21 %) 13 (59 %) 6 (55 %)
othersb 3 (3 %) 0 2 (9 %) 1 (9 %)
Cognitive impairment 15 (16 %) 1 (2 %)**** 7 (32 %) 7 (64 %) <0.0001
Cause of death 0.793
respiratory failure 67 (70 %) 45 (71 %) 14 (64 %) 8 (73 %)
othersc 29 (30 %) 18 (29 %) 8 (36 %) 3 (27 %)
ALS amyotrophic lateral sclerosis
aData are expressed as median (range)
bThree patients developed cognitive impairment or character change before the appearance of motor symptoms. Motor symptoms became evident seven
months after disease onset in one patient (Type 2a), and within a month in the other two patients (Type 2a and Type 2b, respectively)
cInfections, gastrointestinal bleeding or sudden death
*P = 0.024 vs. Type 1 (Kruskal-Wallis test with post-hoc Steel-Dwass test), **P <0.0001 vs. Type 1 and P = 0.003 vs. Type 2a (Kaplan-Meier method and log-rank test),
***P <0.0001 vs. Type 2a and P <0.01 vs. Type 2b (Fisher’s exact test with Bonferroni-corrected multiple comparison test), ****P <0.001 vs. Type 2a and P <0.00001
vs. Type 2b (Fisher’s exact test with Ryan’s multiple comparison test)
Table 2 Pathologic features and phosphorylated TDP-43 pathology in three types of sporadic ALS
Type 1 Type 2a Type 2b P-value
(n = 63) (n = 22) (n = 11)
Neuronal lossa
Motor cortex 2.1 ± 0.7 2.1 ± 0.7 2.5 ± 0.7 0.073
Anterior horns (cervical and lumbar) 2.2 ± 0.5 2.1 ± 0.6 1.5 ± 0.4* 0.002
Hypoglossal nucleus 2.3 ± 0.7 2.1 ± 0.7 1.4 ± 0.5** <0.001
Frontotemporal degeneration (cases) 4 (6 %)*** 8 (36 %) 7 (64 %) <0.0001
pTDP-43 pathology (cases)
NCIs: temporal-predominant type NA 13 (59 %) 5 (45 %) NA
DNs: many in neostriatum and globus pallidus 1 (2 %) 2 (9 %) 9 (82 %)**** <0.0001
ALS amyotrophic lateral sclerosis, pTDP-43 phosphorylated TDP-43, NCI neuronal cytoplasmic inclusion, DN dystrophic neurite, NA non-applicable
a0 = absent, 1 = mild, 2 = moderate, 3 = severe. Data are expressed as mean ± standard deviation
*P <0.001 vs. Type 1 and P = 0.018 vs. Type 2a, **P = 0.001 vs. Type 1 and P = 0.022 vs. Type 2a (Kruskal-Wallis test with post-hoc Steel-Dwass test), ***P <0.001 vs.
Type 2a and P = 0.00001 vs. Type 2b (Fisher’s exact test with Ryan’s multiple comparison test), ****P <0.00001 vs. Type 1 and P <0.0001 vs. Type 2a (Fisher’s exact
test with Ryan’s multiple comparison test)
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comparison with the motor cortex. No pTDP-43-positive
neuronal intranuclear inclusions were evident in any of the
cases examined.
In the subcortical region, pTDP-43-positive granular
and dot-like DNs were a feature of the neostriatum and
globus pallidus in most cases of Type 2b (82 %) (Table 2
and Fig. 2a-c). The rate of occurrence of such pTDP-43
pathology was significantly lower, being only 2 % and
9 %, in Type 1 (P <0.00001) and Type 2a (P <0.0001),
respectively, than in Type 2b. These inclusions were also
detectable with the phosphorylation-independent anti-
TDP-43 antibody (Fig. 2d).
The anatomical localization of pTDP-43 deposits forming
granular and dot-like DNs
SMI-32 and synaptophysin are known to be dendritic and
presynaptic markers, respectively. In the temporal cortex
and globus pallidus, pTDP-43-positive granular and dot-
like structures were observed along the SMI-32-positive
dendrites (Fig. 3a-c and g-i, respectively), and it was evident
that co-localization of pTDP-43 and synaptophysin was not
a feature (Fig. 3d-f and j-l, respectively). Moreover, in the
globus pallidus, it was clear that pTDP-43-positive granular
and dot-like structures were located closely beside
synaptophysin-positive structures (Fig. 3j-l). In the puta-
men, we observed a localization pattern of pTDP-43 similar
to that in the temporal cortex and globus pallidus (data not
shown). These results strongly suggested that deposition of
the pTDP-43 occurred in the dendritic spines.
pTDP-43 inclusion-bearing neurons and oligodendrocytes
in the motor cortex
Next, to investigate the density of NCI-bearing neurons
and GCI-bearing oligodendrocytes, we performed double
labeling with in situ hybridization using a probe for hNF
(mRNA) and immunohistochemistry using an antibody
for pTDP-43 (protein). Brain cells positive for hNF were
recognized as neurons (Fig. 4a i-v), and pTDP-43
inclusion-bearing brain cells negative for hNF were con-
sidered to be glial cells, or more strictly oligodendrocytes
(Fig. 4a iii-v). There was no evidence of any perivascular
distribution of pTDP-43-positive inclusions suggestive of
astrocytic involvement (Fig. 1c); we did not take astrocytes
into consideration.
The density of NCI-bearing neurons was higher in Type
2b than in Type 1 (P = 0.032) (Fig. 4b i), although there was
no difference in the total number of neurons between the
two; the median neuron count per 1 mm2 was 553.8 (inter-
quartile range: 503.7-577.8) for Type 1, 573.7 (516.7-619.7)
for Type 2a, and 575.4 (533.3-650.3) for Type 2b, P = 0.316.
The density of GCI-bearing glial cells was higher in Type
2b than that in Type 1 (P = 0.027) and Type 2a (P = 0.018)
(Fig. 4b ii). The ratio of NCI-bearing neurons to total NCI-
bearing neurons and GCI-bearing glial cells was higher in
Type 2a than in Type 1 (P = 0.004) (Fig. 4b iii), although
Fig. 2 Dendrospinal pTDP-43 pathology in the neostriatum and globus pallidus. (a) Low-magnification view of the basal ganglia from a case
of Type 2b delineates the putamen and globus pallidus with phosphorylated TDP-43 (pTDP-43) immunoreactivity. (b, c) High-magnification
views of the putamen (b) and globus pallidus (c) show numerous pTDP-43-positive granular and dot-like structures. (d) Similar granular and
dot-like structures in the globus pallidus are also visualized using phosphorylation-independent anti-TDP-43. Scale bars: a = 500 μm; b-d = 10 μm.
GPe = external segment of globus pallidus; GPi = internal segment of globus pallidus
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there was no difference in the density of NCI-bearing
neurons between the two (P = 0.114) (Fig. 4b i).
Biochemical and genetic features
The data obtained by immunoblot analysis of sarkosyl-
insoluble fractions are shown in Fig. 5. The anti-
phosphorylated TDP-43 antibody detected a ~45-kDa
band and a ~26-kDa fragment in all cases of ALS and
FTLD-TDP examined. Focusing on the pattern of the
~26-kDa bands, in all cases of sporadic ALS examined,
both the upper (24-kDa) and lower (23-kDa) bands of
the C-terminal fragments of pTDP-43 were clearly
detected, and found to be compatible with those ob-
tained in two cases of FTLD-TDP Type B, and different
from those in FTLD-TDP Type A, showing no evident
differences between the three ALS groups.
Fig. 3 The anatomical localization of pTDP-43 deposits forming granular and dot-like DNs. (a-l) Double-labeling immunofluorescence in the
temporal cortex (a-f) and globus pallidus (g-l) from two different cases of Type 2b. Phosphorylated TDP-43 (pTDP-43)-positive granular and
dot-like structures are observed along SMI-32-positive dendrites (a, g: green, pTDP-43; b, h: red, SMI-32; c, i: merged). No co-localization of
pTDP-43 and synaptophysin is evident (d, j: green, pTDP-43; e, k: red: synaptophysin; f, l: merged). Close association with pTDP-43-positive
structures and synaptophysin-positive structures is observed in the globus pallidus (j-l). There is evidence of contact between pTDP-43- and
synaptophysin-positive structures, suggesting that pTDP-43 is localized in the dendritic spines (l, insert). Scale bars: a-f = 5 μm; g-l = 10 μm
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Fig. 4 Neuronal and glial pTDP-43 pathology in the motor cortex. (a) Double labeling with human neurofilament in situ hybridization (blue)
and phosphorylated TDP-43 (pTDP-43) immunohistochemistry (brown). High-magnification views of pTDP-43-positive NCIs (arrows) and GCIs
(arrowheads) of various shapes in the motor cortex (i-v). pTDP-43-positive GCIs occur exclusively in oligodendrocytes (iii-v), including those
adjacent to neurons (satellite oligodendrocytes) (iii, iv). Scale bar = 10 μm for i-v. (b) Box-plots indicate the density of NCI-bearing neurons
(i) as well as that of GCI-bearing glial cells (ii), and the ratio of NCI-bearing neurons to total NCI-bearing neurons and GCI-bearing glial cells (iii).
Minimum and maximum numbers or percentages are depicted by short horizontal lines, the box signifies the upper and lower quartiles, and the
median is represented by a long horizontal line within the box for each group. P-values shown at the bottom and top of each graph were
calculated by Kruskal-Wallis test and post-hoc Steel-Dwass test, respectively
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With regard to the sequencing of the TDP-43 (TARDBP)
gene in the 83 cases examined, there were no mutations in
the coding regions except for one case with a known
synonymous mutation in exon 6 [36]. No C9ORF72 repeat
expansion was observed.
Discussion
In the present study, a series of 96 cases of sporadic ALS
were classified into three groups on the basis of the cor-
tical pTDP-43 pathology (Fig. 1a). Based on the absence
or presence of pTDP-43-positive NCIs in the hippocam-
pal dentate granule cells, we divided all cases into two
groups, Type 1 and Type 2 (Fig. 1a, b). Among the cases
belonging to Type 2, we noted that some were charac-
terized by the presence of DNs in the affected temporal
neocortex in addition to NCIs (Fig. 1a, c). Accordingly,
we further divided these Type 2 cases into two sub-
groups, i.e. Type 2a and Type 2b, based on the presence
or absence of the prominent appearance of pTDP-43-
positive DNs, irrespective of the amount of NCI-bearing
neurons. Interestingly, statistical analysis revealed a
number of significant differences of clinico-pathologic
features among these three groups, which appeared to
support the validity of this classification (Tables 1, 2).
Comparison of the ubiquitin- or TDP-43-related cor-
tical pathology of FTLD described by many investigators
suggested that Type 2a apparently corresponded to Type
B in the harmonized classification system for FTLD-
TDP pathology reported by Mackenzie et al. (2011) [16,
21, 22, 40, 42], whereas Type 2b showed a very unusual
cortical TDP-43 pathology characterized by many DNs
in the form of threads, and granular and dot-like struc-
tures (Fig. 1c). This pathologic picture appeared to be
somewhat similar to, but by no means consistent with
that of Type A in the classification system mentioned
above (the majority of DNs observed in cases classified
as Type 2b appeared to be smaller structures). Further-
more, immunoblot analysis of sarkosyl-insoluble pTDP-
43 revealed that the band patterns of Type 2b and Type
1 were indistinguishable and differed from those of FTLD-
TDP Type A (Fig. 5). By contrast, Type A pathology and a
FTLD-TDP Type A band pattern have been described in
the motor cortex in two cases of primary lateral sclerosis
(PLS) [33]. Therefore, we conclude that, to our knowledge,
the overall picture of Type 2b is distinct from those
observed in patients with FTLD-U or FTLD-TDP.
From a clinico-pathologic viewpoint, cognitive impair-
ment was much less frequent in patients with Type 1 as
we suggested previously [17]; in other words, its presence
in patients with sporadic ALS strongly suggests Type 2a
or Type 2b. Moreover, Type 2b, although accounting for
only a small proportion of the disease spectrum, could be
regarded as a distinct subset showing a relatively old age
at onset and a shorter survival time than the other two
groups. Patients in this group frequently developed bulbar
symptoms initially (Table 1). From a pathologic viewpoint,
less severe loss of lower motor neurons and the presence
of numerous pTDP-43-positive granular and dot-like DNs
in the putamen and globus pallidus were notable features
in Type 2b (Table 2).
In the present study, clinical information was limited to
that obtained retrospectively from the medical records of
the patients for whom details of some clinical symptoms
were unavailable. This was one of the limitations of the
present study. It has been shown that classification of pa-
tients with ALS based on clinical assessment provides in-
formation for better understanding the wide spectrum of
this motor and cognitive disorder [43]. Moreover, neuro-
pathologic examination of a large-scale cohort of clinically
assessed patients would be expected to reveal pathogno-
monic features responsible for the various symptoms.
The results of double-labeling immunofluorescence
using anti-pTDP-43 antibody and dendritic (SMI-32) or
presynaptic (synaptophysin) markers in the temporal cor-
tex and basal ganglia of patients with Type 2b suggested
that deposition of pTDP-43 might occur in neuronal
dendritic spines (Fig. 3). TDP-43 is normally localized
primarily to the nucleus, where it regulates transcription
Fig. 5 pTDP-43 immunoblot analysis. Immunoblot analysis of sarkosyl-insoluble fractions from the affected cortex of FTLD-TDP Type A, B, and C cases
(two each; upper panels), and Type 1, Type 2a and Type 2b cases (four each; lower panels) immunostained with anti- phosphorylated TDP-43 antibody
(pTDP-43, phospho Ser409/410). In all cases from the three ALS groups, both the upper (24-kDa) and lower (23-kDa) bands of the C-terminal fragments of
pTDP-43 are clearly detected, and the pattern of these fragments is similar to those shown in FTLD-TDP Type B, and not in FTLD-TDP Type A or Type C
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and alternative splicing [12, 32]. In addition, recently, the
roles of TDP-43 in dendrites and spines have been succes-
sively investigated [44, 45]. In neurons, TDP-43 is
expressed abundantly in dendrites mainly in the form of
RNA granules, and translocation of the TDP-43-containing
granules into dendritic spines in response to neuronal activ-
ities has been demonstrated in cultured neurons. Accord-
ingly it has been proposed that TDP-43 is a neuronal
activity-responsive factor functioning in the regulation of
neuronal plasticity [45]. More recently, it has been reported
that disease-linked mutations in TDP-43 alter the dynamics
of neuronal RNA granules during dendritic arborization,
and reduce or slow the response of TDP-43 to changes in
neuronal activity [44]. Considering these findings, it could
be speculated that accumulation of the pathologic protein,
pTDP-43, in neuronal dendritic spines of the cerebral cor-
tex, as well as in the neostriatum and globus pallidus, leads
to a decline in synaptic plasticity, and is at least partly
responsible for the poor prognosis of patients with Type 2b,
mainly through respiratory failure, despite the fact that loss
of lower motor neurons is milder than that seen in patients
with Type 1 and Type 2a.
Comparison of the TDP-43 cellular pathology in the
motor cortex among the three disease groups showed
that both the density of NCI-bearing neurons and GCI-
bearing glial cells were higher in Type 2b than in Type
1. In addition, the ratio of NCI-bearing neurons to all
inclusion-bearing cells was higher in Type 2a than in
Type 1. Propagation of pathologic TDP-43 via axonal
connections has been proposed on the basis of findings
from autopsied ALS brains [46], and it has also been
demonstrated that oligodendroglial involvement by
pathologic TDP-43 precedes neuronal involvement in
the spinal cord in ALS [47]. However, the mechanisms
responsible for the spread of TDP-43 pathology into
multiple systems of the CNS remain uncertain. Our
present findings indicate that the mechanism of cellular
involvement in propagation differs between Type 2b and
Type 2a, oligodendrocytes also being substantially in-
volved, in addition to neurons, in the former.
We consider that the three groups of sporadic ALS
described here are originally independent of each other.
Based on the TDP-43 pathologic staging scheme proposed
by Brettschneider et al. [46], all cases of Type 2 in the
present study corresponded to Stage 4, and the TDP-43
pathology appeared to progress from Stage 1 to 4 during
the disease course. However, in sporadic ALS, we have
previously demonstrated that long-term survival facilitated
by artificial respiratory support has no apparent influence
on the distribution pattern of neuronal inclusions in the
two types (type 1 and type 2) of TDP-43 [17], and that 5
of 6 patients who survived for 10–20 years without re-
spiratory support showed type 1 TDP-43 pathology [48].
Moreover, the present study revealed that survival time
was shorter and that loss of lower motor neurons was less
severe in patients with Type 2b than in those suffering
from Type 1 and Type 2a. Taken together, we concluded
that transition from Type 1 to Type 2, or from Type 2a to
Type 2b, depending on disease duration or progression,
would be unlikely to occur.
None of the patients in the present study had muta-
tions in C9ORF72. Hexanucleotide (GGGGCC) repeat
expansion in a non-coding region of C9ORF72 is the
major genetic cause of FTD and ALS (c9FTD/ALS) in
the Caucasian population [49], but extremely rare in
Japan [38, 50, 51]. When considering the rarity of this
genetic disease in Japan, it is interesting to note that the
reported national incidence rate of ALS in 2009 was 2.3
per 100,000 population [52], being much lower than the
rates reported for Caucasian populations in Europe and
North America [53].
Conclusion
In conclusion, we have demonstrated heterogeneity of
cortical pTDP-43 pathology in sporadic ALS, allowing
the disease to be classified into three groups: Type 1,
and Type 2a and Type 2b. Several significant clinical and
pathologic correlations among these groups were evi-
dent. It was re-confirmed that dementia is not a feature
of Type 1. Furthermore, the distinct subtype, Type 2b,
accompanied by dendrospinal accumulation of pTDP-
43, was shown to be characterized by a poor prognosis
despite the less severe loss of lower motor neurons, the
unusual subcortical dendritic pTDP-43 pathology, and
more prominent glial involvement in cortical pTDP-43
pathology than other two groups. Further studies will be
needed in order to establish the character of this sub-
type, Type 2b. Recognition of the heterogeneity of the
anatomical and cellular localization of pTDP-43 will be
important for clarifying the pathomechanisms involved
in pTDP-43 aggregation and propagation in sporadic
ALS, and eventually for developing future strategies of
treatment and prevention.
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